Patents by Inventor Na Ra OH

Na Ra OH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition for preventing or treating keloids or hypertrophic scars
    Patent number: 11946051
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: April 2, 2024
    Assignee: Tego Science Inc.
    Inventors: Saewha Jeon, Ho Yun Chung, Na Ra Oh, Yun Hee Kim, Jikhyon Han, Hyun Ah Moon
  • COMPOSITION FOR PREVENTING OR TREATING KELOIDS OR HYPERTROPHIC SCARS
    Publication number: 20230124032
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.
    Type: Application
    Filed: November 21, 2022
    Publication date: April 20, 2023
    Applicant: Tego Science Inc.
    Inventors: Saewha JEON, Ho Yun CHUNG, Na Ra OH, Yun Hee KIM, Jikhyon HAN, Hyun Ah MOON
  • COMPOSITION FOR PREVENTING OR TREATING KELOIDS OR HYPERTROPHIC SCARS
    Publication number: 20210388352
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.
    Type: Application
    Filed: December 4, 2019
    Publication date: December 16, 2021
    Applicant: Tego Science Inc.
    Inventors: SaeWha JEON, Ho Yun CHUNG, Na Ra OH, Yun Hee KIM, Jik Hyon HAN, Hyun Ah MOON